Insider Selling: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider Sells 10,223 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 10,223 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $14.73, for a total transaction of $150,584.79. Following the transaction, the insider now owns 612,646 shares in the company, valued at approximately $9,024,275.58. This represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.77, for a total transaction of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.92, for a total value of $253,296.84.

Eton Pharmaceuticals Stock Down 0.9%

Shares of Eton Pharmaceuticals stock traded down $0.13 during midday trading on Monday, hitting $14.17. The company had a trading volume of 324,095 shares, compared to its average volume of 224,421. The company has a fifty day simple moving average of $16.54 and a 200 day simple moving average of $15.05. The stock has a market cap of $380.01 million, a price-to-earnings ratio of -64.41 and a beta of 1.28. Eton Pharmaceuticals, Inc. has a 12-month low of $3.18 and a 12-month high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $17.28 million for the quarter, compared to analyst estimates of $14.33 million. As a group, analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

ETON has been the topic of several analyst reports. B. Riley reiterated a “buy” rating and issued a $26.00 target price (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday, May 29th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Anchor Capital Advisors LLC purchased a new position in Eton Pharmaceuticals during the 4th quarter worth approximately $805,000. Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at about $147,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock worth $2,862,000 after buying an additional 149,864 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its holdings in Eton Pharmaceuticals by 11.3% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company’s stock worth $1,705,000 after acquiring an additional 13,009 shares during the period. Finally, Hillsdale Investment Management Inc. acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $226,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.